Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Landskrona – page 89

1 405 clinical trials in Landskrona, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Landskrona at a glance
1 405
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 405 trials in Landskrona

Open in trial search

Study on Siplizumab and Rabbit Anti-Thymocyte Globulin for Preventing Rejection in New Kidney Transplant Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Itb-Med AB

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Dimenhydrinate
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm

Not recruiting

Study on Repotrectinib for Children and Young Adults with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Alterations

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Repotrectinib
  • Sponsor:Turning Point Therapeutics Inc.

Asthma

Not recruiting

Study on the Effectiveness and Safety of AZD4604 for Adults with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Investigational
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Londamocitinib xinafoate
  • Sponsor:AstraZeneca AB

Factor VIII deficiency+1

Not recruiting

Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Multiple sclerosis+1

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis+2

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Landskrona

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical research focusing on heart failure with preserved ejection fraction (HFpEF), evaluating the effectiveness of spironolactone and eplerenone treatments combined with standard care approaches.

  • Heart Failure Management
  • Cardiovascular Outcomes
  • Treatment Optimization

The research aims to reduce hospitalization rates and improve cardiovascular survival outcomes through registry-based methodologies.

02 Urological Oncology

Groundbreaking research in non-muscle invasive bladder cancer treatment, comparing the efficacy of adjuvant therapies using gemcitabine versus mitomycin in intermediate-risk cases.

  • Bladder Cancer Treatment
  • Recurrence Prevention
  • Post-surgical Care

This study focuses on improving recurrence-free survival rates following transurethral tumor resection procedures.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.